Supernus- Indivior merger reshapes CNS pharma, Q2 revenue beats
All-stock merger with Indivior Supernus agreed to merge with Indivior in an all-stock deal, creating a CNS-focused company with $2.2B pro forma revenue and $125M cost synergies. Supernus shareholders get 1.5401 Indivior shares per share. The combined firm keeps the SUPN ticker and CEO. This is the main driver, boosting scale and pipeline.
The merger is the biggest new event, directly reshaping Supernus and driving the stock's recent surge.
Q2 revenue beat and strong growth Supernus reported Q2 revenue of $211.3 million, up 27.7% year over year and 2.8% above estimates. This shows the core business is growing faster than expected, supporting the stock price.
The Q2 revenue beat is new and confirms operational strength, a key fundamental driver.